Corrigendum to: Subgroup analysis of Japanese patients in a Phase 3 study of atezolizumab in advanced triple-negative breast cancer (IMpassion130)

In the originally approved version of this article, Figures 1(A) and 1(B) were misplaced and thus labelled to incorrectly represent the opposite dataset. Figure 1(A) represented PD-L1-positive patients. Figure 1(B) represented progression-free survival in Japanese patients. The figures have now been placed in their correct locations and are accurately labelled. Figure 1(A) now correctly represents progression-free survival in Japanese patients. Figure 1(B) now correctly represents PD-L1-positive patients.